Search papers, labs, and topics across Lattice.
This editorial discusses the role of the European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology group (PBG) in facilitating translational oncology research across different tumor types. The PBG aims to bridge the gap between pre-clinical research and clinical investigation, supporting biomarker development and validation. The editorial highlights the group's pan-tumor perspective and the increasing involvement of young investigators.
The EORTC Pathobiology group plays a crucial role in advancing translational oncology by fostering collaboration and providing expertise in biomarker development and validation across diverse tumor types.
Progress in precision oncology depends on effective and well-coordinated collaboration between pre-clinical researchers and clinical investigators. In this setting, the European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology group (PBG) plays a key role in reinforcing the link between biological research and clinical investigation, facilitating the translation of biological and medical findings into clinical application, supporting the rigorous testing of molecular hypotheses in clinical trials, and providing multidisciplinary expertise for biomarker development and validation across different tumor types. A defining characteristic of the EORTC PBG is its pan-tumor perspective, which is consistent with the evolving molecular taxonomy of cancer and, through specialized expertise in molecular biology, pathology, biomarker development, and quality assurance, contributes to the activities of both the EORTC Translational Research Division and the Disease-Oriented Groups. This editorial outlines the scientific mission and achievements of the EORTC PBG, highlights the increasing contribution of Young and Early Career Investigators within the group, and emphasizes the importance of pathobiology-driven research in rare cancers, where unmet clinical needs remain considerable.
